C
신라젠
215600KOSDAQ43.5 / 100
Reference Date: 2026-10-23
Financial Score15.0 / 40
News Sentiment12.5 / 25
Momentum6.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Roughly flat over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Shinara Gen is a biotech venture company established in 2006, focusing on developing anti-cancer drugs. The company specializes in oncolytic virus therapies, mitotic checkpoint inhibitors, and generic pharmaceuticals. Its oncolytic viruses selectively target cancer cells and are being studied in combination therapies with immune checkpoint inhibitors.
Number of Employees
56people
Average Salary
82.0M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
2.77Industry Average 1.200.0Point
2.3x industry avg (risky)
ROE
-20.00Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
1.50Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20253.0 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲67.3% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼10.5% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -26.0% (improving, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (11%, downtrend)
Current 2,205Won52-week high 4,97552-week low 1,844
1-month return3.0Point
1m -0.45% (flat)
Volume trend2.0Point
Volume decreasing
Detailed Disclosure
0 totalPositive 0Neutral 0Negative 0